Cargando…

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy

Detalles Bibliográficos
Autores principales:	Furqan, Fateeha, Maring, Morgan, Szabo, Aniko, Fenske, Timothy S., Hamadani, Mehdi, Shah, Nirav N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241849/ https://www.ncbi.nlm.nih.gov/pubmed/36417762 http://dx.doi.org/10.1182/bloodadvances.2022009025

Ejemplares similares

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
por: Furqan, Fateeha, et al.
Publicado: (2022)

P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA
por: Shah, Nirav N, et al.
Publicado: (2023)

Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis
por: Epperla, Narendranath, et al.
Publicado: (2019)

CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients
por: Abid, Muhammad Bilal, et al.
Publicado: (2022)

Intravascular large B‐cell lymphoma treated with polatuzumab‐based salvage therapy: A rare case
por: Bitar, George, et al.
Publicado: (2021)

Polatuzumab vedotin for B-cell lymphoma
Publicado: (2020)

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
por: Zurko, Joanna, et al.
Publicado: (2022)

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
por: Gouni, Sushanth, et al.
Publicado: (2022)

Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
por: Perriello, Vincenzo Maria, et al.
Publicado: (2023)

Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases
por: Gerhardt, Kristin, et al.
Publicado: (2021)

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
por: Dhakal, Binod, et al.
Publicado: (2021)

Autologous stem cell rescue recipient with neutrophil tissue delivery detected prior to blood engraftment: A case report
por: Tbakhi, Bushra, et al.
Publicado: (2020)

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020)

Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Recent Advances in Allogeneic CAR-T Cells
por: Kim, Dong Wook, et al.
Publicado: (2020)

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
por: Lynch, Ryan C., et al.
Publicado: (2022)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
por: Iqbal, Madiha, et al.
Publicado: (2021)

Correction to: Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Excellent Interim Treatment Response with Polatuzumab Vedotin
por: Mehtap, Özgür, et al.
Publicado: (2020)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions
por: Major, Ajay, et al.
Publicado: (2022)

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma
por: Kawasaki, Natsumi, et al.
Publicado: (2022)

Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma
por: Thomas, Colin, et al.
Publicado: (2023)

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Long-term response in refractory AML following azacitidine-failed MDS by salvage decitabine-bridged allogenic transplantation
por: Niscola, Pasquale, et al.
Publicado: (2019)

Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients
por: Douglas, Melanie
Publicado: (2020)

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
por: Shemesh, Colby S., et al.
Publicado: (2020)

Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma
por: Assi, Rita, et al.
Publicado: (2021)

Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
por: Dere, Randall C., et al.
Publicado: (2023)

Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
por: Alanzi, Meshaal, et al.
Publicado: (2023)

Allogeneic CAR-T Cells: More than Ease of Access?
por: Graham, Charlotte, et al.
Publicado: (2018)

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023)

Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma
por: Anderson, Kara, et al.
Publicado: (2020)

Polatuzumab Vedotin for the Front-Line Treatment of Diffuse Large B-Cell Lymphoma: A New Standard of Care?
por: Davis, James A., et al.
Publicado: (2023)

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
por: Topp, Max S., et al.
Publicado: (2022)

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
por: Ababneh, Hazim S., et al.
Publicado: (2023)

Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma
por: Epperla, Narendranath, et al.
Publicado: (2017)

Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis
por: Shah, Nirav N., et al.
Publicado: (2019)

Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes
por: Knight, Jennifer M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0h7o6v7376ain0q57em3f5k3bt